HRs* (and 95% CIs) for occurrence of primary endpoint†according to the baseline serum Lyso-Gb3 levels and the pretreatment Lyso-Gb3 exposure, both per natural log increase
| Baseline Lyso-Gb3 levels | Pretreatment exposure to Lyso-Gb3 | |||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Crude | 2.12 | 1.32 to 3.42 | 0.002 | 3.02 | 1.69 to 5.37 | <0.001 |
| Model 1 | 2.45 | 1.44 to 4.14 | 0.001 | 2.88 | 1.58 to 5.25 | 0.001 |
| Model 2 | 3.75 | 1.44 to 9.73 | 0.007 | 3.69 | 1.60 to 8.51 | 0.002 |
| Model 3 | 4.62 | 1.55 to 13.81 | 0.006 | 3.41 | 1.11 to 10.49 | 0.03 |
*Model 1: adjusted for age at Lyso-Gb3 determination; Model 2: additionally, adjusted for male sex; Model 3: additionally, adjusted for classic phenotype.
†Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic dialysis), new onset of atrial fibrillation, pacemaker and/or implantable cardioverter defibrillator implantation, myocardial infarction, cerebrovascular events (stroke or transient ischaemic attack), death.